[{"Assets_0_Q2_USD":187076000.0,"CommonStockSharesOutstanding_0_Q2_shares":30416028.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-45482000.0,"NetIncomeLoss_1_Q2_USD":-26874000.0,"NetIncomeLoss_2_Q2_USD":-54029000.0,"StockholdersEquity_0_Q2_USD":159414000.0,"Ticker":"RVNC","CIK":"1479290","name":"REVANCE THERAPEUTICS, INC.","OfficialName":"Revance Therapeutics Inc. Common Stock","form":"10-Q","period":"20170630","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1265045755.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20170804"}]